Differential gene regulation during neoadjuvant therapy trial of Epirubicin/cyclophosphamide (EC) docetaxel/capecitabaine (DX) regimens in patients with large ER-positive and ER-negative breast cancer, a randomized Phase II Trial

Objective

The chemotherapy drugs are epirubicin, cyclophosphamide and docetaxed, given by IV infusion, and capecitabine, given by mouth.

IRB Protocol Number

02-824-A

Principal Investigator(s)

ANTHONY ELIAS

Cancer Trials

• Breast Cancer

Sponsor(s)

UCCC

Contact

ANNA NELSON at 720-848-0675
or ANNA.L.NELSON@UCDENVER.EDU

Eligibility and Other Participant Information

What To Expect : There are two different treatments for this trial. Group 1 will receive epirubicin and cyclophosphamide before breast cancer surgery, followed by a combination of dectaxel and capecitabine after surgery. Group 2 will receive docetaxed and capecitabine before surgery, followed by a combination of epirubicin and cyclophosphamide after surgery. The study will last about 8-9 months. We will follow you for life by phone contact. // Eligibility criteria include but are not limited to patients 18 years or older with newly diagnosed breast cancer. There will be a screening period to determine eligibility